0HS8.LSE Lisata Therapeutics
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is 0HS8.LSE undervalued?
Graham numberThe Graham number of Lisata Therapeutics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lisata Therapeutics fundamental analysis
No fundamental analysis for Lisata Therapeutics yet.
Lisata Therapeutics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of …
Full company profileLisata Therapeutics financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lisata Therapeutics annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Operating Income | -29.5M | -27.6M | -17.0M | -20.1M | -19.1M | - | - |
| Net Income | -32.7M | 23.0M | -16.2M | -19.4M | -8.15M | - | - |
| Balance Sheet | |||||||
| Total Assets | 53.5M | 63.4M | 44.6M | 27.2M | 36.0M | - | - |
| Total Liabilities | 48.6M | 12.9M | 6.85M | 6.34M | 3.51M | - | - |
| Shareholders' Equity | 4.88M | 50.5M | 37.7M | 20.8M | 32.5M | - | - |
| Cash & Short-term Investments | 7.08M | 55.1M | 43.1M | 25.2M | 34.6M | - | - |
| Total Debt | 2.68M | - | - | - | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -23.7M | -20.9M | -20.0M | -18.9M | -8.82M | -22.2M | - |
| Capital Expenditure | 1.10M | 135K | 134K | 20.0K | 20.0K | 60.0K | 0.00 |
| Ratios | |||||||
| ROE | -668.7% | 45.5% | -42.9% | -93.0% | -25.1% | - | - |
| ROA | -61.0% | 36.3% | -36.3% | -71.3% | -22.6% | - | - |
| Debt to Equity | 0.55x | - | - | - | - | - | - |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lisata Therapeutics dividends
Lisata Therapeutics has not paid dividends in the last 9 fiscal years.
Last stock split: 0.066667:1 on Sep 15, 2022.
Who owns Lisata Therapeutics
- Insiders 20.57%
- Institutions 11.06%
- Public & others 68.37%
- Free float 6.91M
Lisata Therapeutics company profile
- Company name
- Lisata Therapeutics
- Ticker
- 0HS8.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 21
- Fiscal year end
- December
- Address
- 110 Allen Road, Basking Ridge, NJ, United States, 07920
- Phone
- 908 842 0100
- Website
- lisata.com
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics management
4- Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.CEO & Director · born 1957
- Mr. James NiscoSVP of Finance and Treasury & Chief Accounting Officer · born 1971
- Dr. Joshua Lehrer-Graiwer FACC, M.D.President & COO · born 1974
- Mr. Tariq ImamHead of Human Resources, Senior VP of Business Development & Operations and General Counsel · born 1983